Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)

简要总结

主要结局

次要结局

• To assess the long-term safety in subjects treated with gefitinib by collecting information on: All adverse events that have lead to an interruption/reduction of gefitinib or another intervention(Once, retrospectively for the period the patient has used gefitinib (minimal 3 years))
• long-term safety in subjects; what real life data measures are being taken by lung physicians to counter side effects caused by long term gefitinib treatment; the number, reason, effect and description of interventions that have been taken(Once, retrospectively for the period the patient has used gefitinib (minimal 3 years))
• long-term safety: Number, reason and effect of interruptions during gefitinib use to determine side effects typical for the long-term treatment with gefitinib(Once, retrospectively for the period the patient has used gefitinib (minimal 3 years))